Drug intelligence / Profile preview

DEVA-GT1

Development stage: Preclinical
Lead developer: Devacell
Modality: Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

DEVA-GT1 is a preclinical gene therapy and gene-editing candidate developed by Devacell. It utilizes the company's proprietary ONCoat™ platform, which is a nanoparticle-based synthetic vector derived from engineered adenovirus subtype 5 (Ad5). The ONCoat™ technology is designed to provide systemic delivery of genetic payloads while potentially overcoming the limitations of traditional viral vectors, such as pre-existing immunity and liver sequestration. While the specific genetic target and therapeutic indication for DEVA-GT1 remain undisclosed, the candidate is part of a pipeline focused on leveraging synthetic viral vectors for oncology and infectious diseases.

Beyond the preview

Go deeper on DEVA-GT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DEVA-GT1.

Explore the full profile